Renaissance Capital logo

VIVE News

US IPO Weekly Recap: Goldman's LBO postpones

PBNC

Goldman's LBO, PSAV, failed to price this week and officially postponed its offering on Friday, reflecting the uncertain environment currently faced by investors.  The IPO market is struggling to build momentum amid market volatility and macroeconomic disturbances. Along with continued talks of a Brexit, the Fed declined to raise rates again, and the VIX Volatility Index...read more

Early-stage device maker Viveve Medical prices upsized Nasdaq IPO below expectations at $5

VIVE

Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, raised $14 million by offering 2.7 million shares at $5. The company, which was listed on the OTCQB under the symbol VIVMF, had expected to raise $12.5 million by offering 1.56 million shares at $8 per share. Viveve Medical plans to list on the Nasdaq under the symbol VIVE....read more

US IPO Week Ahead: Goldman LBO leads the way

PSAV

The week ahead will see three IPOs, led by Goldman LBO PSAV which will be accompanied by two smaller deals that are already OTC listed. IPO activity is still sluggish, but the gradual increase in trailing 90 day IPO returns over the past month (from 5.6% to 13%) and IPO index outperformance over the past month (+2% vs. S&P +1.6%) may help increase the number of...read more

Microcap medical device maker Viveve Medical sets terms for $13 million IPO

VIVE

Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, announced terms for its IPO on Thursday. The Sunnyvale, CA-based company plans to raise $12.5 million by offering 1.6 million shares at a price of $8. At the midpoint of the proposed range, Viveve Medical would command a fully diluted market value of $73 million. Viveve...read more